These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 22846865

  • 1. Molecular targeted therapies in hepatocellular carcinoma.
    Tanaka S, Arii S.
    Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
    [Abstract] [Full Text] [Related]

  • 2. Vascular changes in hepatocellular carcinoma.
    Yang ZF, Poon RT.
    Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
    [Abstract] [Full Text] [Related]

  • 3. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
    Lu LC, Shao YY, Chan SY, Hsu CH, Cheng AL.
    Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
    [Abstract] [Full Text] [Related]

  • 4. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL, Yeo W.
    J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
    [Abstract] [Full Text] [Related]

  • 5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 May; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antiangiogenic strategies in hepatocellular carcinoma: current status.
    Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S.
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
    [Abstract] [Full Text] [Related]

  • 13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-Radosavljevic M.
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [Abstract] [Full Text] [Related]

  • 14. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.
    Tanaka S, Arii S.
    Int J Clin Oncol; 2010 Jun; 15(3):235-41. PubMed ID: 20505971
    [Abstract] [Full Text] [Related]

  • 15. Anti-angiogenic therapy for HCC.
    Dufour JF.
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):81-6. PubMed ID: 22419006
    [Abstract] [Full Text] [Related]

  • 16. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M.
    Dig Dis; 2011 Mar; 29(3):273-7. PubMed ID: 21829017
    [Abstract] [Full Text] [Related]

  • 17. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
    Onkologie; 2011 Mar; 34(10):538-42. PubMed ID: 21985853
    [Abstract] [Full Text] [Related]

  • 18. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 19. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy.
    Bishayee A, Darvesh AS.
    Curr Cancer Drug Targets; 2012 Nov 01; 12(9):1095-118. PubMed ID: 22873221
    [Abstract] [Full Text] [Related]

  • 20. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
    Wu XZ.
    Neoplasma; 2008 Nov 01; 55(6):472-81. PubMed ID: 18999874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.